Taken together, these findings highlight the significance of the CD47‐SIRPα signaling axis to tumor immune evasion, as this pathway not only limits innate immune clearance of tumor cells but also acts as a barrier to DC‐driven adaptive immunity to cancer as well. This evidence concerns the gene CD47 and neoplasm.